Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390085 | 0.87 | MEN1 (0.38) | MEN1KMT2ATSHRDPP4ALDH1A1 | |
| SCHEMBL10012603 | 0.82 | TSHR (0.33) | MEN1KMT2ATSHR | |
| SCHEMBL10012641 | 0.82 | TSHR (0.33) | MEN1KMT2ATSHR | |
| SCHEMBL10012604 | 0.82 | TSHR (0.38) | MEN1KMT2ATSHR | |
| SCHEMBL8421539 | 0.82 | NAAA (0.44) | TSHRNAAAALDH1A1EPHX1CYP3A4 | |
| SCHEMBL27982814 | 0.82 | NAAA (0.44) | TSHRNAAAALDH1A1EPHX1CYP3A4 | |
| SCHEMBL23768306 | 0.82 | USP2 (0.41) | MEN1KMT2ANAAAALDH1A1CYP3A4 | |
| SCHEMBL19881228 | 0.81 | NAAA (0.36) | MEN1KMT2ATSHRNAAAEPHX1 | |
| SCHEMBL15506127 | 0.81 | ALDH1A1 (0.52) | MEN1KMT2ATSHRALDH1A1CYP3A4 | |
| SCHEMBL19117261 | 0.81 | MEN1 (0.37) | MEN1KMT2ATSHRDPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | MEN1 3692/4885KMT2A 4458/4885TSHR 1642/4885 |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | MEN1 3570/4885KMT2A 4425/4885TSHR 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.